Loss of muscle mass also flagged, as UK drugmaker works with China’s Eccogene on obesity and type 2 diabetes pill
Weight-loss treatments need to become cheaper and easier to take and lead to less reduction in muscle mass, according to the chief executive of AstraZeneca, which is working with a Chinese company to develop a pill to tackle obesity and type 2 diabetes.
In November, Britain’s biggest drugmaker struck an exclusive licence agreement with Shanghai-based Eccogene, for an experimental drug called ECC5004 that would also treat cardiometabolic conditions such as heart disease and stroke. Obesity and diabetes affect more than 1 billion people globally.
More Stories
Sing when you’re winning: how karaoke in cars heralds the triumph of Chinese firms
RBA interest rates: Reserve Bank of Australia cuts cash rate to 3.85% amid lowering inflation
M&S expects cyber-attack to last into July and cost £300m in lost profits